Open Access · CC BY-NC 3.0
The evaluation and optimal use of rituximab in lymphoid malignancies
Blood and Lymphatic Cancer: Targets and Therapy · 2012
DOI: 10.2147/blctt.s15561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2012. Verfasst von Tadeusz Robak und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Robak, T., Robak, & Smolewski (2012). The evaluation and optimal use of rituximab in lymphoid malignancies. Blood and Lymphatic Cancer: Targets and Therapy. https://doi.org/10.2147/blctt.s15561
Vancouver
Robak T, Robak, Smolewski. The evaluation and optimal use of rituximab in lymphoid malignancies. Blood and Lymphatic Cancer: Targets and Therapy. 2012. doi:10.2147/blctt.s15561
BibTeX
@article{Robak2012,
author = {Robak, Tadeusz and Robak and Smolewski},
title = {The evaluation and optimal use of rituximab in lymphoid malignancies},
journal = {Blood and Lymphatic Cancer: Targets and Therapy},
year = {2012},
doi = {10.2147/blctt.s15561}
}
EUVIMED